ROS-activated anticancer prodrugs: A new strategy for tumor-specific damage

Therapeutic Delivery

Volumn 3, Issue 7, 2012, Pages 823-833

  Peng, Xiaohua ^a   Gandhi, Varsha ^b  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; IMATINIB; PRODRUG; QUINONE DERIVATIVE; QUINONE METHIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DNA ALKYLATION; DNA MODIFICATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LUNG CANCER; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84864591550     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.61     Document Type: Article

References (84)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
2. Venter JC, Adams MD, Myers EW. The sequence of human genome. Science 291, 1304-1351 (2001)
3. Collins FS, Lander ES, Rogers J et al. Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
4. Lander ES. Initial impact of the sequencing of the human genome. Nature 470, 187-197 (2011).
5. Mardis ER. A decade's perspective on DNA sequencing technology. Nature 470, 198-203 (2011).
6. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
7. Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev. 25, 534-555 (2011).
8. Kenefick K. Small-molecule kinase inhibitors: From lab bench to clinic. Cell Notes 16, 26-29 (2006).
9. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 387(4), 365-372 (2006).
10. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794-798 (1991).
11. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: A biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 53, 209-219 (2004).
12. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistant oxidative stress in cancer. FEBS Lett. 358, 1-3 (1995).
13. Arnold RS, Shi J, Murad E et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc. Natl Acad. Sci. USA 98, 5550-5555 (2001).
14. Ishikawa K, Takenaga K, Akimoto M et al ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320, 661-664 (2008).
15. King MS, Sharpley MS, Hirst J. Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (complex I) and production of reactive oxygen species. Biochemistry 48, 2053-2062 (2009).
16. Tsang WP, Chau SP, Kong SK, Kwok TT. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci. 73, 2047-2058 (2003).
17. Vafa O, Wade M, Kern S et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell 9, 1031-1044 (2002).
18. Sahin E, Colla S, Liesa M et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-65 (2011).
19. Afanas'ev I. Reactive oxygen species signaling in cancer: Comparison with aging. Aging Dis. 2, 219-230 (2011).
20. Elchuri S, Oberley TD, Qi WB et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 24, 367-380 (2005).
21. Hole PS, Darley RL, Tonks A Do reactive oxygen species play a role in myeloid leukemias? Blood 117, 5816-5826 (2011).
22. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390-395 (2000).
23. Trachootham D, Zhou Y, Zhang H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252 (2006).
24. Young TW, Mei FC, Yang G, Thompson- Lanza JA, Liu J, Cheng X. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res. 64, 4577-4584 (2004).
25. Laurent A, Nicco C, Chéreau C et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 65, 948-956 (2005).
26. Nicco C, Laurent A, Chereau C, Weill B, Batteux F. Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed Pharmacother. 59, 169-74 (2005).
27. Choi J, Liu RM, Forman HJ. Adaptation to oxidative stress: Quinone-mediated protection of signaling in rat lung epithelial L2 cells. Biochem. Pharmacol. 53, 987-993 (1997).
28. Kim GJ, Chandrasekaran K, Morgan WF. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: A review. Mutagenesis 21, 361-367 (2006).
29. Sheridan J, Wang LM, Tosetto M et al. Nuclear oxidative damage correlates with poor survival in colorectal cancer. Br. J. Cancer 100, 381-388 (2009
30. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: Implications for cancer therapy. Int. J. Biochem. Cell. Biol. 32, 157-170 (2000).
31. Pervaiz S, Clement MV. Superoxide anion: Oncogenic reactive oxygen species? Int. J. Biochem. Cell. Biol. 39, 1297-1304 (2007).
32. Kong D, Park EJ, Stephen AG et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65, 9047-9055 (2005).
33. Wang R, Zhou S, Li S. Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr. Med. Chem. 18, 3168-3189 (2011).
34. Tsai HC, Baylin SB. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 21, 502-517 (2011).
35. O'Hagan HM, Wang W, Sen S et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell. 20, 606-619 (2011).
36. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1a eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 8, 399-411 (2011).
37. Vlaminck B, Toffoli S, Ghislain B, Demazy C, Raes M, Michiels C. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS J. 274, 5533-5542 (2007).
38. Muss HB, Blessing JA, Hanjani P, Malfetano JH, Kemp GM, Webster K. Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A Phase II trial of the gynecologic oncology group. Am. J. Clin. Oncol. 15, 363-364 (1992).
39. Muss HB, Blessing JA, DuBeshter B. Echinomycin in recurrent and metastatic endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group. Am. J. Clin. Oncol. 16, 492-493 (1993).
40. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004).
41. Benito J, Shi Y, Szymanska B et al. Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR-104. PloS ONE 6, e23108 (2011).
42. Patterson AV, Ferry DM, Edmunds SJ et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res. 13, 3922-3932 (2007)
43. Wang J, Yi J. Cancer cell killing via ROS:T o increase or decrease, that is the question. Cancer Biol. Ther. 7, 1875-1884 (2008).
44. Alexandre J, Nicco C, Chéreau C. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J. Natl Cancer Inst. 98, 236-244 (2006).
45. Pelicano H, Feng L, Zhou Y et al. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278, 37832-37839 (2003).
46. Trachootham, D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic appoach? Nat. Rev. Drug. Discov. 8, 579-591 (2009).
47. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and the therapeutic implications. Drug Resist. Update 7, 97-110 (2004).
48. Lopez-Lazaro M. Dual role of hydrogen peroxide in cancer: Possible relevance to cancer chemoprevention and therapy. Cancer Lett. 252, 1-8 (2007).
49. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61, 290-302 (2009).
50. Schumacker PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell. 10, 175-176 (2006).
51. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111 (1999).
52. Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M. Role of reactive oxygen species in cis-diclorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br. J. Cancer 76, 206-210 (1997).
53. Anastasious D, Poulogiannis G, Asara JM et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283 (2011).
54. Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 292, 2083-2086 (2001).
55. Lee KW, Lee HJ, Kang KS, Lee CY. Preventive effects of vitamin C on carcinogenesis. Lancet 359, 172 (2002).
56. Duvoix A, Blasius R, Delhalle S et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 223, 181-190 (2005).
57. Halliwell B. The antioxidant paradox. Lancet 355, 1179-1180 (2000).
58. Alexandre J, Batteux F, Nicco C et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int. J. Cancer 119, 41-48 (2006).
59. Llobet D, Eritja N, Encinas M et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19, 115-124 (2008).
60. Doroshow JH. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J. Natl. Cancer Inst. 98, 223-225 (2006).
61. Denny WA. Prodrugs strategies in cancer therapy. Eur. J. Med. Chem. 36, 577-595 (2001).
62. Raj L, Ide T, Gurkar AU et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234.
63. Doering M, Ba LA, Lilienthal N et al. Synthesis and selective anticancer activity of organochalcogen based redox catalysts. J. Med. Chem. 53, 6954-6963 (2010).
64. Bair JS, Palchaudhuri R, Hergenrother PJ. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death, J. Am. Chem. Soc. 132, 5469-5478 (2010).
65. Major Jourden JL, Cohen SM. Hydrogen peroxide activated matrix metalloproteinase inhibitors: A prodrug approach. Angew. Chem. Int. Ed. 49, 6795-6797 (2010).
66. Kuang Y, Balakrishnan K, Gandhi V, Peng X. Hydrogen peroxide inducible DNA cross-linking agents:T argeted anticancer prodrugs. J. Am. Chem. Soc. 133, 19278-19231 (2011).
67. Hagen H, Marzenell P, Jentzsch E et al. Aminoferrocene-based prodrugs activated by reactive oxygen species. J. Med. Chem. 55(2), 924-934 (2012).
68. Li G, Bell T, Merino EJ. Oxidatively activated DNA-modifying agents for selective cytotoxicity. Chem. Med. Chem. 6, 869-875 (2011).
69. Hillard E, Vessieres A, Thouin L, Jaouen G, Amatore C. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-typed breast cancer drug candidates. Angew. Chem. Int. Ed. 45, 285-290 (2006).
70. Vessieres A, Top S, Pigeon P et al. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro. J. Med. Chem. 48, 3937-3940 (2005).
71. Hamels D, Dansette PM, Hillard EA et al. Ferrocenyl quinone methides as strong antipfoliferative agents: Formation by metabolic and chemical oxidation of ferrocenyl phenols. Angew. Chem. Int. Ed. 48, 9124-9126 (2009).
72. Messina P, Labbe E, Buriez O et al. Deciphering the activation sequence of ferrociphenol anticancer drug candidates. Chem. Eur. J. 18(21), 6581-6587 (2012).
73. Kuivila HG, Armour AG. Electrophilic displacement reactions. IX. Effects of substituents on rates of reactions between hydrogen peroxide and benzeneboronic acid. J. Am. Chem. Soc. 79, 5659-5662 (1957).
74. Yang WQ, Gao X, Wang BH. Boronic Acids Hall DG (Ed.). Wiley-VCH, Weinheim, Germany, 481-512 (2005).
75. Dickinson BC, Chang CJ. A targetable fluorescent probe for imaging hydrogen peroxide in the mitochondria of living cells. J. Am. Chem. Soc. 130, 9638-9639 (2008).
76. Miller EW, Albers AE, Pralle A, Isacoff EY, Chang CJ. Boronate-based fluorescent probes for imaging cellular hydrogen peroxide. J. Am. Chem. Soc. 127, 16652-16659 (2005).
77. Miller EW, Tulyathan O, Isacoff EY, Chang CJ. Moleaular imaging of hydrogen peroxide produced for cell signalling. Nat. Chem. Biol. 3, 263-267 (2007).
78. Srikun D, Miller EW, Domaille DW, Chang CJ. An ICT-based approach to ratiometric fluorescence imaging of hydrogen peroxide produced in living cells. J. Am. Chem. Soc. 130, 4596-4597 (2008).
79. Kaynar H, Meral M, Turhanb H, Kelesc M, Celikb G, Akcayb F. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett. 227, 133-139 (2005).
80. Battisti V, Maders LDK, Bagatini MD et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin. Biochem. 41, 511-518 (2008).
81. Ganesamoni R, Bhattacharyya S, Kumar S et al. Status of oxidative stress in patients with renal cell carcinoma. J. Urol. 187, 1172-1176 (2012).
82. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101, 4098-4104 (2003).
83. Cao S, Wang Y, Peng X. ROS-inducible DNA cross-linking agent as a new anticancer prodrug building block. Chem. Eur. J. 18, 3850-3854 (2012).
84. Seddon B, Kelland LR, Workman P. Bioreductive prodrugs for cancer therapy. Methods Mol. Med. 90, 515-542 (2004).